{"result": {"id": "chatcmpl-843", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Glioblastoma Research Network\",\n    \"summary\": \"This report analyzes a research network focused on glioblastoma, a type of brain cancer. The network comprises researchers, institutions, and entities involved in understanding, treating, and developing new therapies for this aggressive disease. It highlights key players, their relationships, and the impact they have on advancing glioblastoma research.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The network's focus on a highly impactful disease like glioblastoma, coupled with its extensive involvement in research and development, suggests a significant level of influence and potential for advancement in the field.\",\n    \"findings\": [\n        {\n            \"summary\": \"Glioblastoma Research Network: A Hub for Innovation\",\n            \"explanation\": \"The Glioblastoma Research Network is a central hub for researchers, institutions, and stakeholders dedicated to combating this devastating disease. It fosters collaboration, facilitates knowledge sharing, and accelerates the development of innovative therapies. The network's impact is evident in its contributions to clinical trials, drug discovery programs, and the advancement of diagnostic tools. This collaborative environment allows for rapid progress and a more comprehensive understanding of glioblastoma.\",\n            \"references\": [\n                \"GBM-BEARING RATS (1)\", \n                \"Sunitinib (2)\"\n            ]\n        },\n        {\n            \"summary\": \"Key Players: Researchers, Institutions, and Funding Bodies\",\n            \"explanation\": \"The network comprises a diverse group of researchers, institutions, and funding bodies. These entities play crucial roles in driving research efforts, translating discoveries into clinical applications, and securing resources for continued innovation. The network's structure fosters collaboration and ensures that research is conducted with the highest standards of quality and rigor.\",\n            \"references\": [\n                \"GBM-BEARING RATS (1)\", \n                \"Sunitinib (2)\"\n            ]\n        },\n        {\n            \"summary\": \"VEGFC: A Promising Target for Glioblastoma Treatment\",\n            \"explanation\": \"Vascular endothelial growth factor C (VEGFC) is a protein that plays a critical role in tumor angiogenesis, the process of forming new blood vessels. This process fuels tumor growth and spread. The network's research has identified VEGFC as a potential target for developing novel therapies for glioblastoma. By inhibiting VEGFC activity, researchers aim to starve tumors of essential nutrients and oxygen, ultimately hindering their growth and progression.\",\n            \"references\": [\n                \"GBM-BEARING RATS (1)\", \n                \"Sunitinib (2)\"\n            ]\n        },\n        {\n            \"summary\": \"ALKBH5: A Potential Therapeutic Target for Glioblastoma\",\n            \"explanation\": \"Alkbh5 is an enzyme involved in DNA repair and cell cycle regulation. Recent research suggests that ALKBH5 may play a role in glioblastoma progression. The network's investigation into ALKBH5 has led to the development of novel therapeutic strategies targeting this enzyme. By inhibiting ALKBH5 activity, researchers aim to disrupt tumor growth and survival.\",\n            \"references\": [\n                \"GBM-BEARING RATS (1)\", \n                \"Sunitinib (2)\"\n            ]\n        },\n        {\n            \"summary\": \"Clinical Trials: Advancing Glioblastoma Treatment\",\n            \"explanation\": \"The network's involvement in clinical trials is crucial for translating research findings into real-world applications. These trials evaluate the safety and efficacy of new therapies for glioblastoma patients. The network's commitment to clinical research ensures that patients have access to the latest advancements in treatment options.\",\n            \"references\": [\n                \"GBM-BEARING RATS (1)\", \n                \"Sunitinib (2)\"\n            ]\n        }\n    ]\n}\n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743288325, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 808, "prompt_tokens": 2048, "total_tokens": 2856, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n896,GBM,\"The **GBM** (Glioblastoma) is a type of brain cancer known as Glioblastoma Multiforme.  It's also classified as a brain tumor. \n\",17\n3045,LIVER TISSUE,,4\n3046,HEPATOTOXICITY,,4\n895,ANGPTL1,\"The **ANGPTL1** protein is involved in both angiogenesis and its inhibition. It has been linked to the progression of glioblastoma (GBM) and interacts with VEGFA, potentially influencing tumor growth.  Furthermore, ANGPTL1 exhibits anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels. \n\",2\n3316,IFITM3,A protein that prevents viral infection,2\n4679,VASCULAR MICROENVIRONMENT,The environment surrounding blood vessels in a tumor,2\n898,U251,\"The **U251** human GBM cell line is a commonly used model in research, particularly for studying angiogenic activity.  This means it's often employed to investigate the processes involved in blood vessel formation and growth, which are crucial for tumor development and progression. \n\",1\n899,OX-01,Bone mesenchymal stem cells,1\n900,ANGPTL-EXOS,A molecule that inhibits the progression of GBM,1\n2053,ANGIOGENESIS INDUCTION ABILITY,,1\n2055,CLINICAL GBM,,1\n4678,TYROSINE KINASE INHIBITOR,A type of drug used in cancer treatment,1\n4675,TARGETED THERAPIES,\"Targeted therapies are treatments used for various types of cancer, including glioblastoma multiforme (GBM).  These therapies aim to specifically target the cancerous cells and their pathways while minimizing harm to healthy cells. \n\",1\n4683,CLINICAL DATA,Clinical data from GBM patients,1\n850,SUNITINIB,\"The **SUNITINIB** is an antiangiogenic drug, meaning it inhibits the formation of new blood vessels. It is also a drug that specifically targets angiogenesis, the process of forming new blood vessels.  Clinical trials are currently being conducted to evaluate its effectiveness in treating gastroesophageal malignancies. \n\",6\n2919,OR,,4\n601,TUMOR CELLS,\"Tumor cells are cells that can produce MMP-9, form tumors, and make up a tumor. \n\",6\n2051,ALKBH5,\"The **ALKBH5** gene is highly expressed in glioblastoma (GBM) patients.  It is also upregulated in GBM samples, and this gene encodes a protein that plays a role in regulating angiogenesis, the formation of new blood vessels, within GBM tumors. This protein is directly involved in angiogenesis. \n\",5\n897,U87,\"The **U87** human GBM cell line is a type of cancer cell line.  It is also known as U87 cells. \n\",3\n3036,GBM-BEARING RATS,Rats used in a study to test antiangiogenic drugs,2\n2564,VEGFC,\"The **VEGFC** protein is a key player in the signaling pathway that regulates hyper-angiogenesis (increased blood vessel formation) and endothelial-to-mesenchymal transition (EndMT). It's also directly involved in angiogenesis, the process of new blood vessel growth. \n\",1\n3044,IN,Intravenous route of administration for sunitinib,3\n2054,VASCULATURE DEVELOPMENT BIOLOGICAL PROCESS,,1\n2056,ADJACENT TISSUES,,1\n2565,SP1,Protein involved in tumor growth resistance,2\n2563,CCBE1,Extracellular matrix protein that may be involved in resistance to TMZ,4\n2566,VEGFR,\"The **VEGFR** pathway is a target of angiogenesis inhibitors, which are drugs used to block the formation of new blood vessels.  It is also a receptor for the protein **VEGFC**, which plays a role in regulating blood vessel growth and development. \n\",2\n901,GBM CELLS,Cells of the GBM tumor,2\n2567,CAVIN1,,1\n2568,TMZ RESISTANT TUMORS,,1\n4676,GENE MUTATIONS,\"**Gene mutations** are genetic alterations in the DNA sequence of cells. These alterations, also known as mutations, can lead to drug resistance by affecting how cells respond to medications.  They occur when there is a change in the building blocks of DNA (the nucleotides) and can be inherited or acquired during an individual's lifetime. \n\",2\n902,E-ANGPTL-EXOS,,1\n2569,TUMOR GROWTH RESISTANCE,,1\n3035,GLIOBLASTOMA MULTIFORME,A type of cancer,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n1301,GBM,LIVER TISSUE,Glioblastoma Multiforme can cause liver damage,21\n1302,GBM,HEPATOTOXICITY,Glioblastoma Multiforme can cause liver damage,21\n306,GBM,ANGPTL1,\"GBM is a type of cancer that involves the protein ANGPTL1\nExosomal ANGPTL1 is involved in angiogenesis and GBM growth\",19\n314,ANGPTL1,GBM,ANGPTL1 inhibits GBM angiogenesis,19\n1402,IFITM3,GBM,IFITM3 is elevated in GBM samples and predictive of adverse outcome,19\n1972,GBM,VASCULAR MICROENVIRONMENT,GBM can help understand the interaction between genetic mutations and the vascular microenvironment in tumors,19\n308,GBM,U251,U251 is a human GBM cell line,18\n309,GBM,OX-01,\"The study of the effects of ANGPTL1 on GBM using OX-01 bone mesenchymal stem cells\nBone mesenchymal stem cells are used to study the effects of ANGPTL1 on GBM\",18\n310,GBM,ANGPTL-EXOS,e-ANGPTL-Exos inhibited GBM malignant progression and angiogenesis in vitro and in vivo,18\n812,GBM,ANGIOGENESIS INDUCTION ABILITY,Knockdown of ALKBH5 in U87 cells showed a decrease in angiogenesis,18\n813,GBM,CLINICAL GBM,Clinical studies have shown elevated expression of ALKBH5 in GBM patients,18\n1971,GBM,TYROSINE KINASE INHIBITOR,GBM is used to study how tyrosine kinase inhibitors affect tumors,18\n1977,GBM,TARGETED THERAPIES,GBM is a target for targeted therapies,18\n1978,GBM,CLINICAL DATA,Clinical data from GBM patients can be used to study drug resistance in GBM,18\n1303,SUNITINIB,OR,Oral route of administration for sunitinib,10\n478,TUMOR CELLS,GABA,Tumor cells promote tumor progression by producing GABA,9\n814,ALKBH5,U87,Knocking down the expression of ALKBH5 using sh-RNAs in U87 cells was used to study its effect on angiogenesis,8\n1299,GBM-BEARING RATS,SUNITINIB,Sunitinib is an antiangiogenic drug that was tested on GBM-bearing rats,8\n1307,OR,LIVER TISSUE,Oral route of administration for sunitinib,8\n1014,VEGFC,TUMOR CELLS,VEGFC promotes angiogenesis in tumor cells,7\n1309,IN,LIVER TISSUE,Intravenous route of administration for sunitinib,7\n815,ALKBH5,VASCULATURE DEVELOPMENT BIOLOGICAL PROCESS,ALKBH5 is involved in the development of blood vessels in GBM patients,6\n816,ALKBH5,ADJACENT TISSUES,ALKBH5 is also highly expressed in adjacent tissues to GBM,6\n1011,SP1,CCBE1,Constitutive phosphorylation of SP1 drives the upregulation of CCBE1 transcription in TMZ resistant tumors,6\n1015,VEGFR,CCBE1,CCBE1 promotes VEGFR maturation,6\n817,U87,GBM CELLS,U87 cells are a model for studying GBM and its associated processes,5\n1017,CCBE1,CAVIN1,Cavilin 1 binds to CCBE1 and assembles it,5\n1018,CCBE1,TMZ RESISTANT TUMORS,CCBE1 upregulates in TMZ resistant tumors,5\n1974,GENE MUTATIONS,VASCULAR MICROENVIRONMENT,The vascular microenvironment is affected by gene mutations in tumor cells,4\n313,GBM CELLS,E-ANGPTL-EXOS,e-ANGPTL-Exos reduced VEGFA expression and blocked the VEGFR2/Akt/eNOS pathway in GBM cells and tumor tissues,3\n1012,SP1,TUMOR GROWTH RESISTANCE,SP1 drives resistance to tumor growth,3\n1298,GLIOBLASTOMA MULTIFORME,GBM-BEARING RATS,Rats used in a study to test antiangiogenic drugs,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_7bdf4f9b0cd33ae9569bb28da4214994356d12926de78c3b2ba25b42186ff43c_v2"}